Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability